JW

Jane Wasman

Director at Rigel Pharmaceuticals

Jane Wasman is the current Director at Rigel Pharmaceuticals. Jane has held this position since February of 2022. Prior to their current role, Wasman served as a member of the Board of Directors at Cytovia Therapeutics from June 2020 to February 2022. In this role, they were a member of the Corporate Governance, Health Care Compliance Oversight, and Nominating Committee and Scientific & Clinical Trial Advisory Committee.

Wasman has also served as President, International and General Counsel at Acorda Therapeutics, Inc. from January 2004 to December 2019. During their time at Acorda, they were also the Chair of the Board Of Directors and the Chair of Nominations & Governance Committee as well as a Member of Audit, Finance and Compensation Committees.

In addition, Wasman is the founder of JWasman Advisors, a consulting firm that provides advice on corporate governance, litigation, and regulatory compliance issues.

Before their time at Rigel Pharmaceuticals and Cytovia Therapeutics, Wasman was the Vice President/Associate General Counsel at Schering-Plough Corp. from January 1995 to December 2004 where they oversaw litigation, environmental, and M&A matters. Prior to that role, they were a Litigation/Environmental/M&A attorney at Fried Frank from January 1989 to December 1995.

Jane Wasman's educational career includes a challenge of leadership from INSEAD, a Doctor of Law from Harvard Law School, and an A.B. in Psychology from Princeton University.

Timeline

  • Director

    Current role